A role of prostaglandin D2 receptor, CRTH2, on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
The effects of AMD3100, a CXCR4 antagonist, on the bleomycin-induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Source: Eur Respir J 2008; 32: 426-436 Year: 2008
Naftopidil, a selective a1 adrenoceptor antagonist, inhibits the growth of lung fibroblasts and attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2009; 34: 1444-1451 Year: 2009
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007
The treatment of bleomycin-induced lung injury with combination of antioxidants and interleukin-1 receptor antagonist (IL-1ra) Source: Eur Respir J 2002; 20: Suppl. 38, 488s Year: 2002
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Endothelin-1 receptor antagonist prevents hyperoxia-induced parenchymal mechanical impairment in mice Source: Eur Respir J 2004; 24: Suppl. 48, 334s Year: 2004
Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats Source: Eur Respir J 2010; 35: 904-912 Year: 2010
Endothelin receptor antagonists (ERAs) neutralize LPS-induced cytokine release from pulmonary vascular smooth muscle cells (PVSMCs) by down-regulation of CD14 Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018